Patents by Inventor Kangying Li

Kangying Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES
    Publication number: 20230142285
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, including but not limited to leukemia, myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN); and diabetes.
    Type: Application
    Filed: December 17, 2020
    Publication date: May 11, 2023
    Inventors: Wei CAI, Xuedong DAI, Oliver Alexis Georges QUEROLLE, Johannes Wilhelmus John F. THURING, Yingtao LIU, Lianzhu LIU, Yanping XU, Liqiang FU, Ming LI, Lichao FANG, Xianguin DENG, Qiwu ZHAO, Kangying LI, Alicia Tee Fuay NG, Nicolas Freddy J. DARVILLE, Edward CLEATOR, Gregor Thomas URBANIETZ, William Marc MATON, Vineet PANDA
  • Crystalline forms of Acalabrutinib
    Patent number: 11345706
    Abstract: The present invention provides crystalline forms of Acalabrutinib, Specific crystalline forms provided by the present invention include Acalabrutinib Form APO-I, a co-crystal of Acalabrutinib and urea; APO-II, a co-crystal of Acalabrutinib and nicotinamide; APO-III, a co-crystal of Acalabrutinib and L-sorbitol; APO-IV, a crystalline form of Acalabrutinib; and APO-V, a co-crystal of Acalabrutinib and urea.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: May 31, 2022
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Annyt Bhattacharyya, Wancheng Guo, Jingda Zhang, Kun Cheng, Kangying Li
  • Crystalline Forms of Acalabrutinib
    Publication number: 20210130360
    Abstract: The present invention provides crystalline forms of Acalabrutinib, Specific crystalline forms provided by the present invention include Acalabrutinib Form APO-I, a co-crystal of Acalabrutinib and urea; APO-II, a co-crystal of Acalabrutinib and nicotinamide; APO-III, a co-crystal of Acalabrutinib and L-sorbitol; APO-IV, a crystalline form of Acalabrutinib; and APO-V, a co-crystal of Acalabrutinib and urea.
    Type: Application
    Filed: August 23, 2018
    Publication date: May 6, 2021
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Annyt Bhattacharyya, Wancheng Guo, Jingda Zhang, Kun Cheng, Kangying Li
  • Processes for the preparation of Ribociclib and intermediates thereof
    Patent number: 10723739
    Abstract: The present invention provides processes for the preparation of Ribociclib, as well as intermediates useful in the preparation thereof. In particular, processes are provided for the preparation of a compound of Formula (4), and its conversion to Ribociclib (1).
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: July 28, 2020
    Assignee: Apotex Inc.
    Inventors: Daoke Dou, Kangying Li, Fuchang Zhang, Jiang Pei, Wancheng Guo
  • Processes for the Preparation of Ribociclib and Intermediates Thereof
    Publication number: 20190345163
    Abstract: The present invention provides processes for the preparation of Ribociclib, as well as intermediates useful in the preparation thereof. In particular, processes are provided for the preparation of a compound of Formula (4), and its conversion to Ribociclib (1).
    Type: Application
    Filed: May 13, 2019
    Publication date: November 14, 2019
    Inventors: Daoke Dou, Kangying Li, Fuchang Zhang, Jiang Pei, Wancheng Guo
  • Salts of Prostaglandin Analog Intermediates
    Publication number: 20180016230
    Abstract: The present invention relates to crystalline 1-adamantanamine salts, and polymorphic forms thereof, of prostaglandin analog intermediates of formula 3a, 4a and 6a, useful in the preparation of Tafluprost and Lubiprostone and processes for their preparation. The process includes combining 1-adamantanamine, water, an organic solvent, and a compound of Formula 3 or 6, thereby obtaining a suspension. The process also includes isolating the solid salt of Formula 3a or 6a from the suspension.
    Type: Application
    Filed: December 10, 2015
    Publication date: January 18, 2018
    Inventors: Yajun Zhao, Yonggang Li, Uma Kotipalli, Sammy Chris Duncan, Honghai Lv, Kangying Li